checkAd

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Nachrichtenquelle: PR Newswire (engl.)
20.09.2021, 18:53  |  155   |   |   

FN Media Group Presents USA News Group News Commentary

VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ -- USA News Group - Oncology data leader COTA recently released a recent survey where half of the respondents pointed to "Operation Warp Speed" as evidence that cancer treatments can and should be moving forward faster. However, in many ways, 2021 has witnessed several major developments that continue to provide optimism within the oncology field, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC),Roche Holding AG (OTC: RHHBY), Merck &. Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), and Pfizer Inc. (NYSE: PFE).

New preclinical data from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) is demonstrating immunotherapeutic effects of the biotech company's flagship product pelareorep that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. 

Handeln Sie Ihre Einschätzung zu Bristol-Myers Squibb!
Long
Basispreis 53,98€
Hebel 14,67
Ask 0,33
Short
Basispreis 61,85€
Hebel 14,66
Ask 0,35

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

At the The International Conference on Immunotherapy Radiation Combinations which recently wrapped up in Paris, France, the data demonstrated the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model.

In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells. In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.

Compared to single-agent radiotherapy, the pelareorep-radiotherapy combination led to a numerical increase in survival, which reached statistical significance when anti-PD-1 therapy was added to the treatment regimen.

"The observed increases in survival and in the number of anti-cancer immune cells within both primary and abscopal tumors following treatment is indicative of the synergistic immunotherapeutic effects of the pelareorep-radiotherapy combination," said Thomas Heineman, M.D., Ph.D., Global Head of Clinical Development and Operations at Oncolytics. "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study. Together with prior clinical and preclinical data, these results also highlight pelareorep's potential as an enabling technology to enhance the efficacy of a wide range of therapies."

Seite 1 von 4
Oncolytics Biotech Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space FN Media Group Presents USA News Group News Commentary VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ - USA News Group - Oncology data leader COTA recently released a recent survey where half of the respondents pointed to "Operation Warp Speed" as …

Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

DatumTitel
25.10.21Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)
Business Wire (engl.) | Weitere Nachrichten
25.10.21Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection
Business Wire (engl.) | Weitere Nachrichten
25.10.21Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults
Business Wire (engl.) | Weitere Nachrichten
22.10.21BRISTOL-MYERS CVR INVESTORS: December 6, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
Business Wire (engl.) | Weitere Nachrichten
22.10.21FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
Business Wire (engl.) | Weitere Nachrichten
22.10.21European Commission Approves Merck’s KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
Business Wire (engl.) | Weitere Nachrichten
22.10.21Kassenärzte:  großes Interesse an Auffrischungsimpfungen
dpa-AFX | Weitere Nachrichten
22.10.21ROUNDUP: Fast 70 Prozent der Bevölkerung mindestens einmal geimpft
dpa-AFX | Weitere Nachrichten
21.10.21Israel will Touristen Einreise ab November unter Auflagen erlauben
dpa-AFX | Weitere Nachrichten
21.10.21Franzosen mit Impfstoff-Rallye: Neues aus dem w:o-Valneva-Forum: Die zweite Biontech oder ein Jahr zu spät dran?(4) 
wallstreet:online Zentralredaktion | Kommentare